Clinical Trial Search

Primary: Number of Participants With Radiographic Objective Response (OR) — 0 participants

Primary: Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline — 3.71; 3.03 month

Primary: Number of Participants With Overall Response (OR), as Assessed by the Investigator — 18; 18; 36 participants

Primary: Number of Participants Experiencing in Situ Anti-tumor Effect of Tarceva — 8 participants

Primary: Number of Participants With an American College of Rheumatology (ACR) 20 Response at Week 12 — 10; 32 Participants — p=<0.001

Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 subjects

Primary: Quadriceps Muscle Strength — 151; 160 lbs — p=>0.05

Primary: Number of Participants With at Least One Event of Cerebral Neurologic Event, Systemic Thromboembolism, Death From Any Cause, and/or Major Bleeding Until the End of…

Primary: Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax) — -0.33; 0.07; 0.30 mL/sec

Primary: Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement — 12; 20; 7 participants — p=0.30

Primary: Number of Patients With Acute Kidney Injury (AKI). — 13; 13 Participants

Primary: Days Per Week of Cannabis Use. — 3.88; 3.1 Days of cannabis use per week — p=<0.05

Primary: Time to Progression (TTP) — 111; 138; 113 Days

Primary: HbA1c Change From Baseline Week 0 to Week 56 — -1.2; -1.56 percent change — p=0.0381

Primary: Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4 — 360.9; -62.0 Microns